ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Capital Expenditures history
Currency unavailable · from the cash flow
No Capital Expenditures data reported for this period type.
Capital Expenditures vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.62M USD | +113.0% | -56.0% | 13.3% | |
| LTM Mar 2026 | $2.32M USD | -68.6% | -34.5% | 57.6% | |
| FY2025 | $1.45M USD | — | — | 7.8% | |
| LTM Mar 2026 | $981.99K USD | +43.1% | -19.2% | 1.4% | |
| LTM Mar 2026 | €955.79K EUR | +5.0% | +11.4% | 7.1% | |
| LTM Mar 2026 | $871K USD | +153.9% | -44.7% | 2.7% | |
| LTM Mar 2026 | $318.66K USD | -41.5% | -69.0% | 0.7% | |
| LTM Mar 2026 | $106K USD | — | -53.4% | 11.5% | |
| LTM Mar 2026 | $27.51K USD | +48.2% | +11.5% | — | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | +43.1% | -39.6% | 7.4% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.